Shopping Cart

Your shopping cart is currently empty

Ramipril

Name: Ramipril
Brand: TargetMol
SKU: T1645
Price: 31 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Catalog No. T1645Cas No. 87333-19-5

Alias Tritace, HOE-498, Carasel, Altace

Ramipril (Altace) is a long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.

Ramipril

Copy Product Info

🥰Excellent

Purity: 99.93%

Catalog No. T1645Alias Tritace, HOE-498, Carasel, AltaceCas No. 87333-19-5

Ramipril (Altace) is a long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.

Pack Size	Price	USA Warehouse	Global Warehouse
100 mg	$31	In Stock	In Stock
500 mg	$48	In Stock	In Stock
1 g	$89	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$55	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.93%

Appearance:Solid

Color:White

Resource Download

COA LCMS HNMR HPLC

Product Introduction

Bioactivity

Description	Ramipril (Altace) is a long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.
Targets&IC50	ACE:5 nM
In vitro	In spontaneously hypertensive rats, Ramipril significantly inhibits both aortic and pulmonary ACE (ACE Angiotensin Converting Enzyme) activity with an IC50 of approximately 5 mg/kg, without affecting cerebral ACE. When administered slowly, Ramipril lowers blood pressure similar to its effect in vitro on HUVECs (Human Umbilical Vein Endothelial Cells), and compared to other ACE inhibitors, it notably reduces the apoptosis rate induced by lipopolysaccharide. In spontaneously hypertensive rats, Ramipril suppresses systolic blood pressure (SBP) with an IC50 of 1.97 mg/kg. When used in conjunction with AT1 receptor blockers, it synergistically enhances the reduction in SBP. Furthermore, in rats treated with bone morphogenetic protein, Ramipril inhibits beta-cell dysfunction by decreasing monocyte/macrophage permeability, apoptosis, and fibrosis, while also reducing the expression of growth factor genes, the Renin-Angiotensin System (RAS), and inflammatory molecules.
In vivo	Long-term treatment of primary human endothelial cells with Ramipril increases ACE expression, an effect that is blocked by the JNK inhibitor SP600125. In serum-starved endothelial cells in vitro, Ramipril does not promote apoptosis. When applied to cultured endothelial cells, Ramipril enhances the activity of CK2 associated with ACE and increases phosphorylation at the ACE Ser1270 site. However, in cells lacking ACE or possessing the S1270A ACE mutation, Ramipril fails to stimulate nuclear accumulation of c-Jun or activate JNK.
Cell Research	The HUVECs are pretreated with the active metabolites of Ramipril for 24 hours. A serum deprivation method is used to induce apoptosis in the presence of Ramipril for an additional 24 hours. The rate of apoptosis is then determined using flow cytometry with two makers annexinV fluorescein isothiocyanate (FITC+) and propidium iodide (PI).(Only for Reference)
Synonyms	Tritace, HOE-498, Carasel, Altace

Chemical Properties

Molecular Weight	416.51
Formula	C₂₃H₃₂N₂O₅
Cas No.	87333-19-5
Smiles	C([C@@H](N[C@@H](CCC1=CC=CC=C1)C(OCC)=O)C)(=O)N2[C@@]3([C@](C[C@H]2C(O)=O)(CCC3)[H])[H]
Relative Density.	1.200 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 50 mg/mL (120.05 mM), Sonication is recommended.

Ethanol: 41.7 mg/mL (100.12 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2.5 mg/mL (6 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

Ethanol/DMSO

	1mg	5mg	10mg	50mg
1 mM	2.4009 mL	12.0045 mL	24.0090 mL	120.0451 mL
5 mM	0.4802 mL	2.4009 mL	4.8018 mL	24.0090 mL
10 mM	0.2401 mL	1.2005 mL	2.4009 mL	12.0045 mL
20 mM	0.1200 mL	0.6002 mL	1.2005 mL	6.0023 mL
50 mM	0.0480 mL	0.2401 mL	0.4802 mL	2.4009 mL
100 mM	0.0240 mL	0.1200 mL	0.2401 mL	1.2005 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc